- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07739550
Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women
Therapeutic Effects of Low-Intensity Extracorporeal Shock Wave Therapy on Refractory Overactive Bladder Symptoms in Females
Overactive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage. Some women continue to experience these symptoms despite lifestyle changes, behavioral therapy, and medication, or they cannot tolerate or decline medical treatment.
This study will evaluate whether low-intensity extracorporeal shock wave therapy (Li-ESWT), a non-surgical treatment delivered externally over the lower abdomen, can safely improve refractory overactive bladder symptoms in women.
A total of 40 women will be randomly assigned in equal numbers to receive either active Li-ESWT or a sham treatment. Both groups will attend one treatment session each week for six weeks. The sham procedure will be similar to the active treatment in positioning, session duration, and device sound but will not deliver shock wave energy.
Symptoms will be assessed using the validated Arabic version of the 8-item Overactive Bladder Questionnaire (OAB-V8) before treatment and during follow-up. The main purpose of the study is to compare the change in OAB-V8 symptom score between the two groups after one month. Additional assessments at three months will include post-void residual urine volume, information from a 3-day voiding diary, the participant's overall impression of improvement, and any treatment-related adverse events.
The study hypothesis is that Li-ESWT will improve overactive bladder symptoms and quality of life compared with sham treatment.
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Abdelrahman F Senosy, MBBCh
- Puhelinnumero: +02 010 95324741
- Sähköposti: Abdelrahmanadam96@gmail.com
Opiskelupaikat
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypti, 11511
- Ain Shams University Hospital
-
Ottaa yhteyttä:
- Abdelrahman F Senosy, MBBCh
- Puhelinnumero: +2 010 95324741
- Sähköposti: Abdelrahmanadam96@gmail.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Female participants aged 18 to 70 years.
- Symptoms of overactive bladder with an Overactive Bladder Questionnaire 8-Item total score greater than 8.
- Failure of behavioral therapy and medical treatment for overactive bladder.
- Refusal of medical treatment for overactive bladder. Ability to understand the study procedures and provide written informed consent.
Exclusion Criteria:
- Current use of medical treatment for overactive bladder.
- Cardiac pacemaker or metallic implant in the treatment area.
- Coagulation disorder or use of anticoagulants that cannot be temporarily discontinued.
- Active urinary tract infection; participants may be reconsidered after successful treatment and recovery.
- Urinary bladder stones.
- Post-void residual urine volume greater than 100 mL.
- Lower urinary tract surgery within the previous 6 months.
- Previous pelvic radiation therapy.
- History of neuropathic disease.
- Pregnancy or planning to become pregnant.
- Hepatic, renal, or cardiac impairment.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Active Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive active low-intensity extracorporeal shock wave therapy using the PiezoWave 2 focused extracorporeal shock wave therapy device.
Treatment will be administered once weekly for 6 weeks.
Before each session, participants will drink 1000 mL of water, and treatment will begin when the bladder reaches approximately 50% of the participant's functional bladder capacity, confirmed by bladder scan.
The probe will be placed over the lower abdomen approximately two fingerbreadths above the pubic symphysis and directed toward the bladder dome and bilateral bladder walls.
Each session will deliver 1000 impulses to each target area, for a total of 3000 impulses, at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
|
Focused low-intensity extracorporeal shock wave therapy will be delivered using the PiezoWave 2 device.
Each session will deliver a total of 3000 impulses at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
Treatment will be administered once weekly for 6 weeks.
|
|
Huijausvertailija: Sham Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive a sham procedure once weekly for 6 weeks.
The procedure will be similar to the active treatment in participant positioning, bladder preparation, probe placement, session duration, and device sound.
A sham probe or zero-energy device setting will be used so that no therapeutic shock wave energy is delivered.
|
A sham procedure will be administered using the same treatment setup, participant positioning, probe placement, session duration, and device sound as active therapy.
A sham probe or zero-energy setting will be used so that no therapeutic shock wave energy is delivered.
The procedure will be performed once weekly for 6 weeks.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Overactive Bladder Questionnaire 8-Item Total Score
Aikaikkuna: Baseline and 1 month after completion of the 6-week treatment
|
The Arabic-validated Overactive Bladder Questionnaire 8-Item (OAB-V8) will be completed at baseline and 1 month after completion of treatment.
The questionnaire contains 8 items scored from 0 to 5, giving a total score ranging from 0 to 40.
Higher scores indicate greater symptom-related bother.
The outcome will be calculated as the change in total OAB-V8 score from baseline to the 1-month assessment.
|
Baseline and 1 month after completion of the 6-week treatment
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Post-Void Residual Urine Volume at 3 Months
Aikaikkuna: Baseline and 3 months after completion of treatment
|
Post-void residual urine volume will be measured by ultrasound after urination and recorded in milliliters.
The outcome will be calculated as the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Frequency Recorded in a 3-Day Voiding Diary
Aikaikkuna: Baseline and 3 months after completion of treatment
|
Participants will record the timing and number of urination episodes in a 3-day voiding diary.
The outcome will assess the change in urinary frequency from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Mean Voided Urine Volume Recorded in a 3-Day Voiding Diary
Aikaikkuna: Baseline and 3 months after completion of treatment
|
The volume of urine passed during each urination will be recorded in milliliters in a 3-day voiding diary.
Mean voided volume will be calculated, and the change from baseline to the 3-month follow-up assessment will be evaluated.
|
Baseline and 3 months after completion of treatment
|
|
Urgency Level Recorded in a 3-Day Voiding Diary
Aikaikkuna: Baseline and 3 months after completion of treatment
|
Participants will record the level of urinary urgency associated with each urination episode in a 3-day voiding diary.
The outcome will assess the change in recorded urgency level from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Leakage Episodes Recorded in a 3-Day Voiding Diary
Aikaikkuna: Baseline and 3 months after completion of treatment
|
The number of involuntary urinary leakage episodes will be recorded over 3 consecutive days.
The outcome will be calculated as the change in the number of leakage episodes from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Functional Bladder Capacity
Aikaikkuna: Baseline and 3 months after completion of treatment
|
Functional bladder capacity will be derived from measurements recorded in the participant's 3-day voiding diary and expressed in milliliters.
The outcome will assess the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
- Kiireellinen virtsankarkailu
- Nocturia
- Virtsan kiireellisyys
- Virtsaamistaajuus
- Matalaintensiteettinen ekstrakorporaalinen shokkiaaltoterapia
- Tulenkestävä yliaktiivinen virtsarakko
- Female Lower Urinary Tract Symptoms
- Functional Bladder Capacity
- Post-Void Residual Urine
- Sham-Controlled Clinical Trial
- Overactive Bladder Questionnaire, 8-Item
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Miesten urogenitaaliset sairaudet
- Urologiset sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Alempien virtsateiden oireet
- Urologiset ilmenemismuodot
- Virtsarakon sairaudet
- Patologiset tilat, merkit ja oireet
- Merkit ja oireet
- Virtsarakko, yliaktiivinen
- Nocturia
Muut tutkimustunnusnumerot
- FMASU MS 434/2026
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .